1521-60-4

Upstream product

• 608-50-4 2,4-dinitromesitylene 
• 696621-31-5 acetic acid-(2,4,6-trimethyl-3-nitro-anilide) 
• 88-05-1 2,4,6-trimethylaniline 
• 7664-93-9 sulfuric acid 
• 108-67-8 1,3,5-trimethyl-benzene 
• 5096-21-9 N-mesitylacetamide 

Downstream Products

• 386-66-3 2-fluoro-1,3,5-trimethyl-4-nitro-benzene 
• 67396-77-4 2-chloro-1,3,5-trimethyl-4-nitrobenzene 
• 250651-03-7 2,4,6-trimethyl-3-nitro-benzonitrile 
• 696621-31-5 acetic acid-(2,4,6-trimethyl-3-nitro-anilide) 
• 1719-21-7 2,4,6-Trimethyl-3-nitro-phenol 
• 101575-60-4 (+/-)-N-benzenesulfonyl-N-(2,4,6-trimethyl-3-nitro-phenyl)-glycine 
• 106567-41-3 2,4,6-trimethyl-3-nitrobenzoic acid 
• 102017-27-6 N-benzenesulfonyl-N-(2,4,6-trimethyl-3-nitro-phenyl)-glycine methyl ester 
• 101575-60-4 (+)-N-benzenesulfonyl-N-(2,4,6-trimethyl-3-nitro-phenyl)-glycine 
• 101575-60-4 (-)-N-benzenesulfonyl-N-(2,4,6-trimethyl-3-nitro-phenyl)-glycine 
• 392-61-0 1,3-difluoro-2,4,6-trimethylbenzene 
• 363-64-4 1,3,5-trimethyl-2,4,6-trifluorobenzene 
• 444-03-1 3-fluoro-2,4,6-trimethyl-aniline 
• 67396-82-1 3-chloro-2,4,6-trimethylaniline 

Relevant academic research and scientific papers

Enantiospecific Synthesis of Nepetalactones by One-Step Oxidative NHC Catalysis

An efficient oxidative NHC-catalyzed one-step transformation of (S)-or (R)-8-oxocitronellal to nepetalactone (NL) in enantio- A nd diastereomerically pure form has been developed. Several new and "easy to make" N-Mes-or N-Dipp-substituted 1,2,4-triazolium salts carrying nitroaromatic groups on N1 were synthesized and evaluated as precatalysts in combination with base and stoichiometric organic oxidant. Under optimized conditions, NLs are accessible in very good yields and diastereomerically pure under mild conditions. The oxidant used could be recovered and recycled under operationally simple conditions.

Benzo heterocyclic derivatives

Provided is a compound of general formula (I) as a potassium channel regulator and pharmaceutically acceptable equivalents thereof. The compound can be used in the preparation of medicines for increasing the ion flow in the potassium channel of mammals or

TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF

The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.